Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
Now I think people will say it was because of the fat loss
Research shows Indians often develop type 2 diabetes at a BMI of 2325 a weight at which most Western medical guidelines wouldn't even consider screening for diabetes
Helps maintain lean muscle during training
Maxwell felt she had lost part of her identity when she was seen first as the fat person. Losing weight finally let her be seen as herselfas Cassiebut would regaining it erase a part of her identity again
Rather, it facilitates overall weight loss by helping patients consume fewer calories, which leads to reduction in total body fat, including visceral and subcutaneous abdominal fat